Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.560 -1.620 (-19.80%)
Streaming Delayed Price Updated: 3:44 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why Myriad Genetics (MYGN) Stock Is Down Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 19.3% in the morning session after it reported mixed third-quarter results that were overshadowed by a weak earnings outlook. 
Via StockStory
Topics Economy Government World Trade
MYGN Q3 Deep Dive: Oncology Growth and Product Launches Offset Market Headwinds
Genetic testing company Myriad Genetics (NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year... 
Via StockStory
Myriad Genetics’s (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock Drops
Genetic testing company Myriad Genetics (NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year... 
Via StockStory
Earnings Scheduled For November 3, 2025
 
Via Benzinga
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
From Myriad Genetics, Inc.
Via GlobeNewswire
What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results this Monday after the bell. Here’s what to expect. 
Via StockStory
Exploring Myriad Genetics's Earnings Expectations
 
Via Benzinga
New Post-Hoc Analysis Shows Patients Whose Clinicians Had Access to GeneSight Results for Depression Treatment Are More Likely to Feel Better Sooner
Faster initial remission and response, persistent benefit over six months 
From Myriad Genetics, Inc.
Via GlobeNewswire
1 Stock Under $10 Worth Your Attention and 2 Facing Challenges
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
Via StockStory
Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025
From Myriad Genetics, Inc.
Via GlobeNewswire
2 Unpopular Stocks That Deserve a Second Chance and 1 That Underwhelm
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
Myriad Genetics Adds F8, FXN Genes to Foresight Universal Plus Panel
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations 
From Myriad Genetics, Inc.
Via GlobeNewswire
3 Cash-Burning Stocks with Open Questions
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to... 
Via StockStory
Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
Breast Cancer Awareness Month: Patient and Clinician Share Insights on how to tackle the fear of cancer screenings on YourUpdateTV
From D S Simon
Via GlobeNewswire
A Look Back at Therapeutics Stocks’ Q2 Earnings: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Pack
Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Myriad Genetics (NASDAQ:MYGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
3 Unprofitable Stocks That Fall Short
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
3 Small-Cap Stocks That Concern Us
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
From Myriad Genetics, Inc.
Via GlobeNewswire
Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Biogen... 
Via StockStory
Topics Artificial Intelligence
1 Momentum Stock for Long-Term Investors and 2 Facing Challenges
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro... 
Via StockStory
3 Russell 2000 Stocks with Open Questions
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
Topics Regulatory Compliance
Myriad Genetics Announces Precise MRD Clinical Data Published in The Lancet Oncology
From Myriad Genetics, Inc.
Via GlobeNewswire
New Meta-Analysis Demonstrates that Access to the GeneSight Test Can Significantly Improve Response and Remission Rates for Patients with Depression
Results published in the Journal of Clinical Psychopharmacology 
From Myriad Genetics, Inc.
Via GlobeNewswire
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
3 Stocks Under $10 We Approach with Caution
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
Via StockStory
Opendoor, SmartRent, Myriad Genetics, Reddit, and Unity Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the major indices continued to pull back, with technology stocks accounting for most of the market's largest decliners. A key reason for this... 
Via StockStory
Topics Artificial Intelligence Economy World Trade
ANGLE Announces Collaboration with Myriad Genetics
Via ACCESS Newswire
Myriad Genetics Appoints Ben Wheeler Chief Financial Officer
From Myriad Genetics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.